Lufenuron (Novartis). Oct 2, 1998. Oral dosage form new animal drugs; Lufenuron Tablets. Final Rule. Federal Register.

FLUORIDE ACTION NETWORK
Lufenuron (Novartis). October 2, 1998. Oral Dosage Form New Animal Drugs; Lufenuron Tablets. Final Rule. Federal Register.
http://frwebgate5.access.gpo.gov/cgi-bin/waisgate.cgi?WAISdocID=1030029466+0+0+0&WAISaction=retrieve
[Federal Register: October 2, 1998 (Volume 63, Number 191)]
[Rules and Regulations]               
[Page 52968]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02oc98-9]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

 
Oral Dosage Form New Animal Drugs; Lufenuron Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a supplemental new animal drug 
application (NADA) filed by Novartis Animal Health US, Inc. The 
supplemental NADA provides for revising the specifications and 
conditions of use of lufenuron tablets for dogs and cats for control of 
flea populations.

EFFECTIVE DATE: October 2, 1998.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for 
Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-594-1612.

SUPPLEMENTARY INFORMATION: Novartis Animal Health US, Inc., P.O. Box 
26402, Greensboro, NC 27404-6402, filed supplemental NADA 141-035 that 
provides for revising the specifications and conditions of use of 
Program<SUP>TM</SUP> (lufenuron) tablets for prevention and control of 
flea populations in dogs and control of flea populations in cats. The 
supplemental NADA is approved as of August 1, 1998, and the regulations 
are amended by revising 21 CFR 520.1288 to reflect the approval. The 
basis of approval is discussed in the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
data and information submitted to support approval of this application 
may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 
between 9 a.m. and 4 p.m., Monday through Friday.
    The agency has determined under 21 CFR 25.33(d)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.

List of Subjects in 21 CFR Part 520

    Animal drugs.
    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

    1. The authority citation for 21 CFR part 520 continues to read as 
follows:
    Authority: 21 U.S.C. 360b.
    2. Section 520.1288 is revised to read as follows:


Sec. 520.1288   Lufenuron tablets.

    (a) Specifications--(1) Dogs. Each tablet contains either 45, 90, 
204.9, or 409.8 milligrams (mg) of lufenuron.
    (2) Cats. Each tablet contains either 90, 135, 204.9 or 270 mg of 
lufenuron.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Minimum of 10 mg of 
lufenuron per kilogram (4.5 mg per pound (lb)) of body weight.
    (2) Indications for use. For use in dogs and puppies, 6 weeks of 
age and older, for the prevention and control of flea populations. 
Lufenuron controls flea populations by preventing the development of 
flea eggs and does not kill adult fleas. Concurrent use of insecticides 
may be necessary for adequate control of adult fleas.
    (3) Limitations. Administer tablet(s) after or in conjunction with 
a full meal to ensure adequate absorption. Administer tablet(s) once a 
month. All dogs and cats in a household should be treated to achieve 
maximum efficacy.
    (d) Conditions of use in cats--(1) Amount. Minimum of 30 mg of 
lufenuron per kilogram (13.6 mg/lb) of body weight.
    (2) Indications for use. For use in cats and kittens, 6 weeks of 
age and older, for the control of flea populations. Lufenuron controls 
flea populations by preventing the development of flea eggs and does 
not kill adult fleas. Concurrent use of insecticides may be necessary 
for adequate control of adult fleas.
    (3) Limitations. Administer tablet(s) after or in conjunction with 
a full meal to ensure adequate absorption. Administer tablet(s) once a 
month. All dogs and cats in a household should be treated to achieve 
maximum efficacy.

    Dated: September 20, 1998.
Margaret Ann Miller,
Acting Director, Office of New Animal Drug Evaluation, Center for 
Veterinary Medicine.
[FR Doc. 98-26423 Filed 10-1-98; 8:45 am]
BILLING CODE 4160-01-F